A critical look at local-regional management of peritoneal metastasis.

Abstract

For patients with stage IV colorectal cancer, the presence of peritoneal metastases is a poor prognostic feature. Despite the improvement in systemic therapy, long-term survival remains poor for patients with peritoneal carcinomatosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be associated with long-term survival in patients who have limited peritoneal disease, particularly those who can have complete cytoreduction. Whether the possible benefit of CRS and HIPEC is from the surgical resection of all disease or the combination of CRS and HIPEC remains unclear.

• Authors: Carlos H F Chan, James C Cusack, David P Ryan
• Journal: Hematology/oncology clinics of North America (Hematol Oncol Clin North Am) Vol. 29 Issue 1 Pg. 153-8 (Feb 2015) ISSN: 1558-1977 [Electronic] United States
• PMID: 25475577 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Colorectal Neoplasms (mortality, pathology, therapy)
• Combined Modality Therapy
• Cytoreduction Surgical Procedures
• Disease Management
• Humans
• Hyperthermia, Induced
• Peritoneal Neoplasms (mortality, secondary, therapy)
• Treatment Outcome